These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 28644771)

  • 1. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
    Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK
    J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
    Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L
    JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
    Gan HK; Millward M; Hua Y; Qi C; Sai Y; Su W; Wang J; Zhang L; Frigault MM; Morgan S; Yang L; Lickliter JD
    Clin Cancer Res; 2019 Aug; 25(16):4924-4932. PubMed ID: 30952639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
    Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN
    Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
    Schuller AG; Barry ER; Jones RD; Henry RE; Frigault MM; Beran G; Linsenmayer D; Hattersley M; Smith A; Wilson J; Cairo S; Déas O; Nicolle D; Adam A; Zinda M; Reimer C; Fawell SE; Clark EA; D'Cruz CM
    Clin Cancer Res; 2015 Jun; 21(12):2811-9. PubMed ID: 25779944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
    Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
    Yang JJ; Fang J; Shu YQ; Chang JH; Chen GY; He JX; Li W; Liu XQ; Yang N; Zhou C; Huang JA; Frigault MM; Hartmaier R; Ahmed GF; Egile C; Morgan S; Verheijen RB; Mellemgaard A; Yang L; Wu YL
    Invest New Drugs; 2021 Apr; 39(2):477-487. PubMed ID: 33052556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
    Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
    Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Savolitinib for MET-driven papillary renal cell carcinoma.
    Gilbert JA
    Lancet Oncol; 2017 Aug; 18(8):e440. PubMed ID: 28669737
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
    Choueiri TK; Vaishampayan U; Rosenberg JE; Logan TF; Harzstark AL; Bukowski RM; Rini BI; Srinivas S; Stein MN; Adams LM; Ottesen LH; Laubscher KH; Sherman L; McDermott DF; Haas NB; Flaherty KT; Ross R; Eisenberg P; Meltzer PS; Merino MJ; Bottaro DP; Linehan WM; Srinivasan R
    J Clin Oncol; 2013 Jan; 31(2):181-6. PubMed ID: 23213094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Savolitinib Heads for Phase III Trial in PRCC.
    Cancer Discov; 2017 Sep; 7(9):OF4. PubMed ID: 28724523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data.
    Albiges L; Heng DYC; Lee JL; Walker S; Mellemgaard A; Ottesen L; Frigault MM; L'Hernault A; Wessen J; Choueiri T; Cancel M; Signoretti S
    Eur J Cancer; 2022 Jul; 170():158-168. PubMed ID: 35640484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
    Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Li J; Luo X; Wang L; Ren Y; Su W
    Lancet Respir Med; 2021 Oct; 9(10):1154-1164. PubMed ID: 34166627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
    Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
    Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Double-Blind, Placebo- and Positive-Controlled, Three-Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.
    Sahota T; Dota CD; Vik T; Yan W; Verheijen RB; Walker S; Li Y; Goldwater R; Ghiorghiu D; Mellemgaard A; Ahmed GF
    Clin Pharmacol Drug Dev; 2021 May; 10(5):521-534. PubMed ID: 33400845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
    Suárez C; Larkin JMG; Patel P; Valderrama BP; Rodriguez-Vida A; Glen H; Thistlethwaite F; Ralph C; Srinivasan G; Mendez-Vidal MJ; Hartmaier R; Markovets A; Prendergast A; Szabados B; Mousa K; Powles T
    J Clin Oncol; 2023 May; 41(14):2493-2502. PubMed ID: 36809050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
    Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
    Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.
    Yang Y; Ricketts CJ; Vocke CD; Killian JK; Padilla-Nash HM; Lang M; Wei D; Lee YH; Wangsa D; Sourbier C; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Ball MW; Srinivasan R; Linehan WM
    Genes Chromosomes Cancer; 2021 Jun; 60(6):434-446. PubMed ID: 33527590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.